Merck + Co., Inc.

Thomas W Miller

Sheldon B Zimmerman

Eugene L Dulaney

Mary E Valiant

Robert E Ormond

Sara A Currie

James P Springer

Kenneth E Wilson

Sagrario M Del Val

George E Albers-Schonberg

Richard W Burg

Hyman Wallick

Sagrario Mochales Del Val

L-654,040 of the structure: ##STR1## is a novel antibacterial and isolated from the novel organism Streptoverticillium synroense, strain MA6011, deposited at the ATCC.

L-654,040, antibacterial agent

Process for producing L-654,040, antibacterial agent

The novel organism Streptoverticillium synroense, strain MA6011, deposited at the ATCC under Accession No. ATCC 53699 produces a novel antibacterial of the structure: ##STR1##

Culture of Streptoverticillium synroense for producing an antibacterial

Novel compounds are produced by the fermentation of a nutrient medium with the previously undescribed microorganism Streptomyces avermitilis. They may be isolated by solvent extraction and chromatographic fractionation techniques. The compounds, which are described generically as C-076 have significant parasiticidal activity. The compounds may be included in compositions for the oral or parenteral administration to animals for the prevention and cure of parasitic infections.

Strain of Streptomyces for producing antiparasitic compounds

Novel compounds are produced by the fermentation of a nutrient medium with the previously undescribed microorganism Streptomyces avermitilis. They may be isolated by solvent extraction and chromatographic fractionation techniques. The compounds, which are described generically as C-076 have significant parasiticidal activity. The compounds may be included in compositions for the oral or parenteral administration to animals for the treatment of parasitic infections.

Novel substances and process for their production

Disclosed is crystalline N-formimidoyl thienamycin and a process for its preparation.

Crystalline N-formimidoyl thienamycin

This case relates to a novel process which aids in the isolation and purification of novel compounds which are produced by the microorganism, Streptomyces avermitilis. The process described utilizes a non-aqueous extraction system for purifying crude extracts of the novel compounds. The compounds which are isolated and purified are described generically as C-076 and have significant parasiticidal activity.

Method for the separation and purification of antibiotic macrolides

This case relates to a novel process which aids in the isolation and purification of novel compounds which are produced by the microorganism, Streptomyces avermitilis. The process described utilizes a column containing a hydroxyalkylated dextran gel as a step in the separation of the desired compounds. The compounds which are isolated and purified are described generically as C-076 and have significant parasiticidal activity.

Growing community of inventors

Carteret, NJ, United States of America

Thomas W Miller